PharmaPoint:帕金森氏症 - 巴西的醫藥品的預測與市場分析
PharmaPoint: Parkinson's Disease - Brazil Drug Forecast and Market Analysis to 2022
|出版日期||內容資訊||英文 167 Pages
|PharmaPoint:帕金森氏症 - 巴西的醫藥品的預測與市場分析 PharmaPoint: Parkinson's Disease - Brazil Drug Forecast and Market Analysis to 2022|
|出版日期: 2014年03月31日||內容資訊: 英文 167 Pages||
Parkinson's disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson's disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.
The decline in sales is attributed to a private-public partnership (PPP) between Brazil and Boehringer Ingelheim, which will drive down the price of generic pramipexole as the technology to produce the drug is transferred to Brazil's Oswaldo Cruz Foundation (Fiocruz)/Institute of Drug Technology (Farmanguinhos), which will solely be responsible for the country's production of the drug by 2017.